Last data update: Mar 21, 2025. (Total: 48935 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Grinnell M[original query] |
---|
Trends in otitis media and myringotomy with tube placement among American Indian and Alaska Native children and the U.S. general population of children after introduction of the 13-valent pneumococcal conjugate vaccine
Singleton R , Seeman S , Grinnell M , Bulkow L , Kokesh J , Emmett S , Holve S , McCollum J , Hennessy T . Pediatr Infect Dis J 2017 37 (1) e6-e12 BACKGROUND: American Indian/Alaska Native (AI/AN) children have experienced higher otitis media (OM) outpatient visit rates than other United States (US) children. To understand recent trends, we evaluated AI/AN OM rates before and after 13-valent pneumococcal conjugate vaccine introduction. METHODS: We analyzed outpatient visits listing OM as a diagnosis among AI/AN children <5 years of age from the Indian Health Service National Patient Information Reporting System for 2010-2013. OM outpatient visits for the general US child population < 5 years of age were analyzed using the National Ambulatory Medical Care and National Hospital Ambulatory Care Surveys for 2010-2011. RESULTS: The 2010-2011 OM-associated outpatient visit rate for AI/AN children (63.5 per 100/year) was similar to 2010-2011 rate for same-aged children in the general US population (62.8), and decreased from the 2003-2005 AI/AN rate (91.4). Further decline in AI/AN OM visit rates were seen for 2010-2011 to 2012-2013 (p-value<0.0001). The AI/AN infant OM visit rate (130.5) was 1.6 fold higher than the US infant population. For 2010-2011, the highest AI/AN OM visit rate for <5 year olds was from Alaska (135.0). CONCLUSION: AI/AN < 5 year old OM visits declined by one-third from 2003-2005 to 2010-2011 to a rate similar to the US general population <5 years. However, the AI/AN infant OM rate remained higher than the US infant population. The highest AI/AN < 5 year old OM rate occurred in Alaska. |
Evaluation of emergency drug releases from the Centers for Disease Control and Prevention Quarantine Stations
Roohi S , Grinnell M , Sandoval M , Cohen NJ , Crocker K , Allen C , Dougherty C , Jolly J , Pesik N . J Emerg Manag 2015 13 (1) 19-23 The Centers for Disease Control and Prevention (CDC) Quarantine Stations distribute select lifesaving drug products that are not commercially available or are in limited supply in the United States for emergency treatment of certain health conditions. Following a retrospective analysis of shipment records, the authors estimated an average of 6.66 hours saved per shipment when drug products were distributed from quarantine stations compared to a hypothetical centralized site from CDC headquarters in Atlanta, GA. This evaluation supports the continued use of a decentralized model which leverages CDC's regional presence and maximizes efficiency in the distribution of lifesaving drugs. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 21, 2025
- Content source:
- Powered by CDC PHGKB Infrastructure